Home / Business and Economy / Crystalys Taps Pharma Vet Walbert as Chairman
Crystalys Taps Pharma Vet Walbert as Chairman
23 Sep
Summary
- Tim Walbert named Chairman, boosting leadership for gout drug dotinurad.
- Seth Fischer joins board, bringing extensive pharma operating experience.
- DeAnne Reid promoted to Chief Administrative Officer, expanding executive team.
Crystalys Therapeutics Inc., a biopharmaceutical company focused on gout treatments, has announced key leadership appointments. Tim Walbert, who previously served as Chairman, President, and CEO of Horizon Therapeutics, has been appointed Chairman of Crystalys' Board of Directors. He has been an Independent Director since January 2026.
Seth H.Z. Fischer, former Chief Executive Officer of Vivus and a seasoned executive from Johnson & Johnson, has joined the Board of Directors. He represents Catalys Pacific on the board. Furthermore, DeAnne Reid has been promoted to Chief Administrative Officer, enhancing the company's executive leadership as it scales operations.
These appointments are pivotal as Crystalys advances its clinical-stage drug, dotinurad, through its registrational program. Co-Founder Dr. BT Slingsby will transition from Executive Chairman to a Board Observer role for Catalys Pacific.
